I
TOKYO, Jan 31 (Reuters) - Japanese trading and pharmaceutical company Kowa Co Ltd (7807.T) said on Monday anti-parasite drug ivermectin has been found effective for treating the Omicron variant of COVID-19 in a Phase III trial.
The trial found ivermectin has "an antiviral effect" against the variant, Kowa said without providing further details. The firm has been working with Kitasato University, a medical university in Tokyo.
Clinical trials evaluating the drug, which is used to treat parasites in animals and humans, are ongoing but promotion of the drug as a COVID-19 treatment has generated controversy.
The drug is not approved for treatment of COVID-19 in Japan and the U.S. Federal Drug Administration has repeatedly warned against its use.
Eno leto našega življenja vrženega stran za brez veze. Koliko nepotrebnih mrtvih.
Zakaj? ZARADI DENARJA!
hmmm....
"The trial found ivermectin has "an antiviral effect" against the variant, Kowa said without providing further details."
Vsak lahko proizvaja Ivermectin. Je off-patent od, mislim da , 1996.In to farmacevtsko podjetje, ki nima veze z Covid-19, ima pa možnost proizvajati (in tržiti) iverco...
Super.Bo prisla ven studija, nic bat.
Pises o Pfizerjevi studiji za njihovo Covid cepivo?Super.
Držimo pesti, da se tudi za to ne izkaže kaj, kar bremeni ostale študije ivrce.
Kot so izmišljeni pacienti, ponarejanje rezultatov, slaba izvedba, majhen/neprimeren vzorec, zavajujoča interpretacija rezultatov,...
V bistvu se cakam na Oxfordsko univerzo, da najde manjkajoci Ivermectin, da zakljucijo njihov Principal trial.Počakaj da nalepi Cedevito ...